Chemical Works of Gedeon Richter's EBIT per Share for the
three
months ended in Dec. 2025 was $0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $2.65.
During the past 12 months, the average EBIT per Share Growth Rate of Chemical Works of Gedeon Richter was 21.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 18.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 21.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 20.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Chemical Works of Gedeon Richter's EBIT per Share or its related term are showing as below:
RGEDF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14.5 Med: 11.3 Max: 34.3
Current: 18
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Chemical Works of Gedeon Richter was 34.30% per year. The lowest was -14.50% per year. And the median was 11.30% per year.
RGEDF's 3-Year EBIT Growth Rate is ranked better than 66.3% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs RGEDF: 18.00
Chemical Works of Gedeon Richter (OTCPK:RGEDF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Chemical Works of Gedeon Richter EBIT per Share Related Terms
Chemical Works of Gedeon Richter EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter (RGEDF) has a EBIT per Share of $2.65 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chemical Works of Gedeon Richter and its competitors. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #273 out of 810 companies in the Drug Manufacturers industry, placing it in the top 33.7%.
Is Chemical Works of Gedeon Richter's EBIT per Share too high?
Chemical Works of Gedeon Richter's current EBIT per Share is $2.65. The Drug Manufacturers industry median EBIT per Share is 7.65. Chemical Works of Gedeon Richter's value of $2.65 is 65.4% below this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #273 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #273 out of 810 companies for EBIT per Share. This puts Chemical Works of Gedeon Richter in the upper half of its industry. The industry median EBIT per Share is 7.65. Chemical Works of Gedeon Richter's value of $2.65 is 65.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current EBIT per Share of $2.65 is 65.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current EBIT per Share is $2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $35.23, compared to a current price of $39.64 — trading 12.5% above its estimated fair value. The current EBIT per Share is $2.65 and 65.4% below the Drug Manufacturers industry median of 7.65. Chemical Works of Gedeon Richter's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current EBIT per Share is $2.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $39.64 is trading 12.5% above its estimated GF Value™ of $35.23.
GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.
Key valuation signals for RGEDF:
EBIT per Share: $2.65
GF Value™: $35.23 vs. price of $39.64 (12.5% above fair value)
Industry Position: 65.4% below the Drug Manufacturers median (#273 of 810)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter Business Description
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
94GF Score
Get the complete analysis for RGEDF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
